ClinicalTrials.gg
RecruitingNCT07631637Updated Nov 9, 2026

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 2 interventional study of ALN-CIDEB and Placebo in Metabolic Dysfunction-Associated Steatohepatitis and MASH, sponsored by Regeneron Pharmaceuticals. Recruiting at 24 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 9, 2026Now RecruitingFirst sites in Puerto Rico, United States and United Kingdom+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Planned enrollment
32nd of 460
360 · median 56
Started
2026
with 7 others
Phase 2
192 of 547
15 open now
Primary completion
2029-01
later than 70 of 92 live
Registered
546th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 32nd largest by planned enrollment of the 460 interventional ones that give a count, is one of 8 that started in 2026, is one of 192 in phase 2, reaches primary completion later than 70 of the 92 other live ones, and was the 546th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH.

In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver injury, and liver scarring. The study will compare ALN-CIDEB with placebo to understand how well ALN-CIDEB works to lower the amount of fat in the liver.

The study is looking at:

  • What side effects ALN-CIDEB might cause
  • How well ALN-CIDEB works to change liver fat, liver injury, and liver scarring
  • How the body and the liver change after having ALN-CIDEB, which can help researchers understand why ALN-CIDEB works better for some people than others
03

Conditions studied

  • Metabolic Dysfunction-Associated Steatohepatitis
  • MASH

Keywords

  • F2 or F3 MASH
  • Fibrotic MASH
  • Nonalcoholic Fatty Liver Disease
  • NAFLD
  • Metabolic dysfunction-Associated Steatotic Liver Disease
  • MASLD
  • Liver Inflammation
  • Liver Fibrosis
  • Cirrhosis
  • Gene silencing
  • siRNA
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. A diagnosis of MASH documented in the participant's medical history, or a clinical suspicion of MASH based on non-invasive biomarkers and clinical risk factors, including having a history of 1 or more elements of metabolic syndrome as described in the protocol
  2. Screening percutaneous liver demonstrating a NAFLD Activity Score (NAS) ≥4 and fibrosis stage F2 or F3 as described in the protocol
  3. Has a FibroScan (FAST) score >0.35 either at Screening Visit 1 or within approximately 3 months of Screening Visit 1 as described in the protocol

Key Exclusion Criteria:

  1. Known chronic liver disease other than Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), as determined by the investigator as described in the protocol
  2. Prior or current suspected or known drug-induced liver injury within approximately 1 year prior to Screening Visit 1
  3. History of liver transplantation, current placement on a liver transplant list, or MELD score >12
  4. Known history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion
  5. Prior, current, or planned future use of a Glucagon-Like Peptide-1 (GLP-1) receptor agonist-based therapy or any medication approved for the treatment of MASH unless used at a generally stable dose and regimen since at least 3 months prior to Screening Visit 1 or the qualifying historical liver biopsy and use is continued throughout the screening period with no change to the dose or regimen anticipated during the treatment period as described in the protocol

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    ALN-CIDEB Dose 1

    Drug: ALN-CIDEB

  • Experimental
    ALN-CIDEB Dose 2

    Drug: ALN-CIDEB

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugALN-CIDEB

    Administered per the protocol

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Liver Fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF)

    Time frame: At week 52

Secondary outcomes

  1. Resolution of MASH with No Worsening of Nonalcoholic Steatohepatitis-Clinical Research Network (NASH-CRN) Fibrosis on Liver Biopsy

    Time frame: At week 52

  2. Improvement of NASH-CRN Fibrosis Stage (F) by ≥1 with No Worsening of MASH on Liver Biopsy

    Time frame: At week 52

  3. Percent Change from Baseline in Liver Fat by MRI-PDFF

    Time frame: At week 26

  4. Achievement of a ≥30% Reduction in Liver Fat by MRI-PDFF Compared to Baseline

    Time frame: At week 52

  5. Achievement of ≤5% Liver Fat by MRI-PDFF

    Time frame: At week 52

  6. Percent Change from Baseline in Liver Fat by MRI-PDFF for Each Dose Level of ALN-CIDEB Compared to Placebo

    Time frame: Up to week 52

  7. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to week 64

  8. Severity of TEAEs

    Time frame: Up to week 64

  9. Change from Baseline in FibroScan Controlled Attenuation Parameter (CAP)

    Time frame: Through week 52

  10. Change from Baseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)

    Time frame: Through week 52

  11. Change from Baseline in Aspartate Aminotransferase (AST)

    Time frame: Up to week 64

  12. Change from Baseline in Alanine Aminotransferase (ALT)

    Time frame: Up to week 64

  13. Change from Baseline in Enhanced Liver Fibrosis (ELF)

    Time frame: Through week 52

  14. Change from Baseline in PRO-C3

    Time frame: Through week 52

  15. Change from Baseline in ADAPT

    Time frame: Through week 52

  16. Change from Baseline in NIS2+

    Time frame: Through week 52

  17. Percent Change from Baseline in Liver Fat by MRI-PDFF in Genetic Subpopulations

    Time frame: At week 52

07

Study locations

24 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2029, 30 months after the start.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 30 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Feb 2029 → Jan 2029 and completion Feb 2029 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 8, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jan 29, 2029was Feb 2029
CompletionEst.
Jan 29, 2029was Feb 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
24 sites added — first sites in Puerto Rico, United States and United Kingdom
Show 24 added (22 United States, 1 Puerto Rico, 1 United Kingdom)
  • Adobe Clinical Research · Tucson, United States
  • The Institute for Liver Health II LLC dba Arizona Liver Health · Tucson, United States
  • Del Sol Research Management, LLC · Tucson, United States
  • California Liver Research Institute · Pasadena, United States
  • Inland Empire Clinical Trials · Rialto, United States
  • Universal Axon Clinical Research · Doral, United States
  • Genoma Research Group, Inc. · Miami, United States
  • Med Research of Florida, LLC · Miami, United States
  • Tandem Clinical Research · Marrero, United States
  • Tandem Clinical Research · Metairie, United States
  • American Research Corporation · Austin, United States
  • Advanced Medical Trials · Georgetown, United States
  • Pioneer Research Solutions, Inc. · Houston, United States
  • American Research Corporation at The Texas Liver Institute · San Antonio, United States
  • Siena Research Network · Sugar Land, United States
  • Fundacion de Investigacion (FDI) Clinical Research · San Juan, Puerto Rico
  • Southwest General Healthcare Center · Fort Myers, United States
  • Indiana University School of Medicine · Indianapolis, United States
  • Kansas Medical Clinic · Topeka, United States
  • Geisinger Medical Center · Danville, United States
  • Quality Medical Research - Nashville · Nashville, United States
  • Texas Clinical Research Institute, LLC · Arlington, United States
  • Methodist Dallas Medical Center · Dallas, United States
  • The Newcastle upon Tyne Hospitals NHS Trust · Newcastle upon Tyne, United Kingdom
across 2 updates, Oct 26, 2026 – Nov 9, 2026
Start date
Jul 15, 2026→Jul 6, 2026 (actual)
Oct 26, 2026
Primary completion
Feb 6, 2029→Jan 29, 2029
Oct 26, 2026
Study completion
Feb 6, 2029→Jan 29, 2029
Oct 26, 2026
Enrollment
150→360
Nov 9, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedKnown history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion and/or a score on the AUDIT questionnaire ≥8
  • EditedPrior, current, or planned future use of a Glucagon-Like Peptide-1 (GLP-1) receptor agonist-based therapy or any medication approved for the treatment of MASH unless used at a generally stable dose and regimen since at least 3 months prior to Screening Visit 1 or the qualifying historical liver biopsy and use is continued throughout the screening period with no change to the dose or regimen anticipated during the treatment period as described in the protocol
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF)Time frame: At week 26 → At week 52
Nov 9, 2026
Secondary outcomes
15 edited
What changed in the outcomes
  • EditedResolution of MASH with no worseningNo Worsening of Nonalcoholic Steatohepatitis-Clinical Research Network (NASH-CRN) fibrosisFibrosis on liver biopsyLiver BiopsyTime frame: At week 52
  • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by MRI-PDFFTime frame: At week 52 → At week 26
  • EditedAchievement of a ≥30% reductionReduction in liver fatLiver Fat by MRI-PDFF Compared to BaselineTime frame: At week 52
  • EditedAchievement of ≤5% liver fatLiver Fat by MRI-PDFFTime frame: At week 52
  • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by MRI-PDFF for each dose levelEach Dose Level of ALN-CIDEB Compared to PlaceboTime frame: Up to week 52
  • EditedImprovement of NASH-CRN Fibrosis Stage (F) by ≥1 with no worseningNo Worsening of MASH on Liver BiopsyTime frame: At week 52
  • EditedChange from baselineBaseline in FibroScan Controlled Attenuation Parameter (CAP)Time frame: Through week 52
  • EditedChange from baselineBaseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)Time frame: Through week 52
  • EditedChange from baselineBaseline in Aspartate Aminotransferase (AST)Time frame: Up to week 64
  • EditedChange from baselineBaseline in Alanine Aminotransferase (ALT)Time frame: Up to week 64
  • EditedChange from baselineBaseline in Enhanced Liver Fibrosis (ELF)Time frame: Through week 52
  • EditedChange from baselineBaseline in PRO-C3Time frame: Through week 52
  • EditedChange from baselineBaseline in ADAPTTime frame: Through week 52
  • EditedChange from baselineBaseline in NIS2+Time frame: Through week 52
  • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by MRI-PDFF in genetic subpopulationsGenetic SubpopulationsTime frame: At week 52
Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    8 sites added — first site in United Kingdom
    Show 8 added (7 United States, 1 United Kingdom)
    • Southwest General Healthcare Center · Fort Myers, United States
    • Indiana University School of Medicine · Indianapolis, United States
    • Kansas Medical Clinic · Topeka, United States
    • Geisinger Medical Center · Danville, United States
    • Quality Medical Research - Nashville · Nashville, United States
    • Texas Clinical Research Institute, LLC · Arlington, United States
    • Methodist Dallas Medical Center · Dallas, United States
    • The Newcastle upon Tyne Hospitals NHS Trust · Newcastle upon Tyne, United Kingdom
    Enrollment 150→360
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedKnown history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion and/or a score on the AUDIT questionnaire ≥8
    • EditedPrior, current, or planned future use of a Glucagon-Like Peptide-1 (GLP-1) receptor agonist-based therapy or any medication approved for the treatment of MASH unless used at a generally stable dose and regimen since at least 3 months prior to Screening Visit 1 or the qualifying historical liver biopsy and use is continued throughout the screening period with no change to the dose or regimen anticipated during the treatment period as described in the protocol
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF)Time frame: At week 26 → At week 52
    Secondary outcomes 15 edited
    What changed in the outcomes
    • EditedResolution of MASH with no worseningNo Worsening of Nonalcoholic Steatohepatitis-Clinical Research Network (NASH-CRN) fibrosisFibrosis on liver biopsyLiver BiopsyTime frame: At week 52
    • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by MRI-PDFFTime frame: At week 52 → At week 26
    • EditedAchievement of a ≥30% reductionReduction in liver fatLiver Fat by MRI-PDFF Compared to BaselineTime frame: At week 52
    • EditedAchievement of ≤5% liver fatLiver Fat by MRI-PDFFTime frame: At week 52
    • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by MRI-PDFF for each dose levelEach Dose Level of ALN-CIDEB Compared to PlaceboTime frame: Up to week 52
    • EditedImprovement of NASH-CRN Fibrosis Stage (F) by ≥1 with no worseningNo Worsening of MASH on Liver BiopsyTime frame: At week 52
    • EditedChange from baselineBaseline in FibroScan Controlled Attenuation Parameter (CAP)Time frame: Through week 52
    • EditedChange from baselineBaseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)Time frame: Through week 52
    • EditedChange from baselineBaseline in Aspartate Aminotransferase (AST)Time frame: Up to week 64
    • EditedChange from baselineBaseline in Alanine Aminotransferase (ALT)Time frame: Up to week 64
    • EditedChange from baselineBaseline in Enhanced Liver Fibrosis (ELF)Time frame: Through week 52
    • EditedChange from baselineBaseline in PRO-C3Time frame: Through week 52
    • EditedChange from baselineBaseline in ADAPTTime frame: Through week 52
    • EditedChange from baselineBaseline in NIS2+Time frame: Through week 52
    • EditedPercent changeChange from baselineBaseline in liver fatLiver Fat by MRI-PDFF in genetic subpopulationsGenetic SubpopulationsTime frame: At week 52
    + 2 other changes: verification date and conditions
  2. Oct 26, 2026
    Not yet recruiting→Recruiting
    16 sites added — first sites in Puerto Rico and United States
    Show 16 added (15 United States, 1 Puerto Rico)
    • Adobe Clinical Research · Tucson, United States
    • The Institute for Liver Health II LLC dba Arizona Liver Health · Tucson, United States
    • Del Sol Research Management, LLC · Tucson, United States
    • California Liver Research Institute · Pasadena, United States
    • Inland Empire Clinical Trials · Rialto, United States
    • Universal Axon Clinical Research · Doral, United States
    • Genoma Research Group, Inc. · Miami, United States
    • Med Research of Florida, LLC · Miami, United States
    • Tandem Clinical Research · Marrero, United States
    • Tandem Clinical Research · Metairie, United States
    • American Research Corporation · Austin, United States
    • Advanced Medical Trials · Georgetown, United States
    • Pioneer Research Solutions, Inc. · Houston, United States
    • American Research Corporation at The Texas Liver Institute · San Antonio, United States
    • Siena Research Network · Sugar Land, United States
    • Fundacion de Investigacion (FDI) Clinical Research · San Juan, Puerto Rico
    Start date Jul 15, 2026→Jul 6, 2026 (now actual)
    Primary completion Feb 6, 2029→Jan 29, 2029
    Study completion Feb 6, 2029→Jan 29, 2029
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07631637
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Jul 6, 2026
Primary completion
Jan 29, 2029 (estimated)
Completion
Jan 29, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion